Insider Sell‑Offs at Aquestive Therapeutics: Corporate Secretary Offloads 135,690 Shares Amid Quiet Executive Shake‑Up
Insightful insider sales at Aquestive Therapeutics reveal routine equity management, yet the company’s bullish pipeline and 89.5% YTD rally signal cautious optimism for investors.
3 minutes to read